… study, GBP1 was significantly upregulated in erlotinib‑resistant cells, compared with
erlotinib‑sensitive cells… GBP1 expression contributed to erlotinib resistance, while decreased …

… tumor cells that carry T790M) will be greater in afatinib-resistant tumor cells than in
erlotinib-resistant tumor cells… In the phase III EURTAC study, erlotinib conferred significant PFS …

… erlotinib [13]. Currently, afatinib has been approved as a first-line treatment for patients with
advanced non-small cell lung cancer … The primary objective of this study is to compare the …

… In the present research, we proposed and validated a novel method for the simultaneous
analysis of five EGFR-… Informed consent was obtained from all individuals included in this study. …

… In the phase I/II KEYNOTE-021 study that evaluated the feasibility of combining erlotinib
or gefitinib with pembrolizumab, pembrolizumab combined with gefitinib was found not to be …

… Erlotinib is also a competitive inhibitor of TK, and gefitinib or … 2007): Randomized phase III
study of cisplatin plus irinotecan … -small-cell lung cancer: Four-Arm Cooperative Study in Japan…

… This study aims to characterize the tumor … -small cell lung cancer treated with erlotinib, and
investigate the relationship between baseline circulating tumor DNA (ctDNA) data and tumor …

… [ 11 C]erlotinib identifies non-small cell lung carcinoma (NSCLC) tumors … studies, [ 11 C]erlotinib
was co-injected with erlotinib (6.7 mg/kg) [20], whereas in the present study, erlotinib …

… The EMERGING-CTONG 1103 study is the first randomised … targeted therapy with erlotinib
compared with standard … study and found that the median OS of neoadjuvant erlotinib …

… Consistent with previous studies, our results showed that EGF … to gefitinib or erlotinib in
EGFR-mutant cells. The predictive … erlotinib therapy was enrolled for the analysis in this study. …